ExoDiscovery Technologies Inc.

ExoDiscovery Technologies Inc. , based in the US, specializes in advanced technologies designed for cancer detection and monitoring, focusing on innovative exosome-based products that enhance early diagnosis and personalized treatment options. ExoDiscovery Technologies Inc. was founded in 2018 by co-founders Kyu Lee, and Yoon Cho, in Cedar Park, US, focusing on innovative cancer diagnostics.

In December 2025, ExoDiscovery Technologies Inc. raised USD 4. 02 million in seed funding. The seed funding values ExoDiscovery Technologies Inc.

at USD 151. 10 million post-money. ExoDiscovery specializes in advanced cancer detection and monitoring technology through its proprietary exosome-based products, ExoDiscovery Detect and ExoDiscovery Monitor. The core offering, ExoDiscovery Detect, focuses on ultra-sensitive screening for high-risk individuals, particularly targeting early detection of pancreatic cancer in patients with hereditary risk factors.

This technology leverages RNA biomarkers encapsulated within exosomes, allowing for detection at concentrations significantly lower than traditional methods, thus improving sensitivity to over 97% across all cancer stages. Complementing this, ExoDiscovery Monitor provides oncologists with real-time insights into treatment efficacy and early signs of resistance, particularly in lung cancer cases. The company primarily serves oncologists, healthcare institutions, and research organizations in North America, with aspirations to expand its offerings into additional geographical markets, enhancing personalized medicine capabilities for cancer care. ExoDiscovery generates revenue through direct partnerships and B2B transactions with healthcare providers and medical institutions.

The company’s flagship products, ExoDiscovery Detect and ExoDiscovery Monitor, facilitate cancer diagnostics and treatment monitoring, which are sold as part of comprehensive service agreements that typically include testing kits, analytical reports, and ongoing support. These agreements are structured to provide healthcare professionals with the tools necessary for timely and effective cancer management. While specific pricing plans for the services are not disclosed, the revenue model encompasses subscription-based services, ensuring continued access to the latest advancements in cancer detection and monitoring technology, aligning with the company's mission to optimize pathways in cancer care. The company will use the December 2025 funds to support commercialization of ExoDiscovery’s EDM liquid‑biopsy platform, expand CLIA‑lab operations in Texas, advance early lung‑cancer detection technology, accelerate clinical validation, and prepare for broader U.

S. market deployment.